Nirma Limited has disclosed the sale of 36,80,000 equity shares in Alivus Life Sciences Limited, representing approximately 2.99% of the total share capital. This transaction, executed via the Open Market on November 6, 2026, resulted in a change of shareholding by Nirma Limited, previously the promoter, from 74.73% to 71.74%. The disclosure is made in compliance with SEBI’s Substantial Acquisition of Shares and Takeovers Regulations.
Promoter Sells Stake in Alivus Life Sciences
Nirma Limited has officially reported the disposal of a significant portion of its shareholding in Alivus Life Sciences Limited. The company sold 36,80,000 equity shares, amounting to 2.99% of the total share capital, on November 6, 2026. This transaction was conducted through the Open Market.
Shareholding Changes
Prior to this sale, Nirma Limited held 9,18,96,285 equity shares in Alivus Life Sciences Limited, representing a 74.73% stake. Following the disposal, Nirma’s shareholding has reduced to 8,82,16,285 equity shares, which constitutes 71.74% of the total share capital. This change in shareholding is in excess of 2% and has been disclosed as per the requirements of Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
Key Transaction Details
The sale has been recorded as occurring on November 6, 2026. The total equity share capital of Alivus Life Sciences Limited before the transaction was Rs. 24,59,34,562 (12,29,67,281 Equity Shares of Rs. 2 each), and it remained the same after the sale. The total diluted share capital also saw a minor change, concluding at Rs. 24,65,63,958 (12,32,81,979 Equity Shares of Rs. 2 each).
Source: BSE
